Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2019  |  Volume : 32  |  Issue : 4  |  Page : 1447-1451

Evaluation of intravitreal injection of ranibizumab in diabetic macular edema


1 Department of Ophthalmology, Faculty of Medicine, Menoufia University, Menoufia, Egypt
2 Department of Ophthalmology, Health Insurance Organization, Shobra El Kheema, Qalubeya, Egypt

Correspondence Address:
Ahmed Z Zayed
El Bajour, El Menoufia 32821
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/mmj.mmj_410_18

Rights and Permissions

Objectives The aim of this study was to evaluate the intravitreal injection of antivascular endothelial growth factor of ranibizumab in patients with diabetic macular edema (DME). Background The study evaluated short-term and long-term effects of ranibizumab on the morphology and function of the retina. Patients and methods Fifty eyes of 44 patients with DME were enrolled in this prospective study. After intravitreal ranibizumab injection, central macular thickness (CMT) and best-corrected visual acuity (BCVA) were measured before, 1, 2, 3, and 6 months later. Results The mean CMT and logarithm of minimum angle of resolution BCVA improved significantly (P < 0.001) after the first, second, and third injections. Three eyes did not show improvement in CMT while seven eyes did not show improvement in BCVA. The most significant (P < 0.0001) correlation in mean CMT and logarithm of minimum angle of resolution BCVA is seen after the first month. In addition, significant change is seen in CMT (P = 0.001, 0.002) and BCVA (P = 0.0001, 0.001) between the first and second month and second and third month, respectively. Three months after the last injection, mean CMT insignificantly (P = 0.24) increased, and mean BCVA insignificantly (P = 0.51) decreased, but they were still significant with baseline. There was a significant correlation (P < 0.001) between the mean change in CMT and BCVA at all stages of the study. Conclusion In DME, intravitreal ranibizumab effectively decreased CMT as a structural aspect and hence improved BCVA as a functional aspect. Evaluation of the short-term effects of ranibizumab can predict the therapeutic outcome 1 month after injection.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed327    
    Printed5    
    Emailed0    
    PDF Downloaded44    
    Comments [Add]    

Recommend this journal